» Articles » PMID: 33902569

Readmissions and Costs Among Younger and Older Adults for Targeted Conditions During the Enactment of the Hospital Readmission Reduction Program

Overview
Publisher Biomed Central
Specialty Health Services
Date 2021 Apr 27
PMID 33902569
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The Hospital Readmissions Reduction Program (HRRP) was introduced to reduce readmission rates among Medicare beneficiaries, however little is known about readmissions and costs for HRRP-targeted conditions in younger populations. The primary objective of this study was to examine readmission trends and costs for targeted conditions during policy implementation among younger and older adults in the U.S.

Methods: We analyzed the Nationwide Readmission Database from January 2010 to September 2015 in younger (18-64 years) and older (≥65 years) patients with acute myocardial infarction (AMI), heart failure (HF), pneumonia, and acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Pre- and post-HRRP periods were defined based on implementation of the policy for each condition. Readmission rates were evaluated using an interrupted time series with difference-in-difference analyses and hospital cost differences between early and late readmissions (≤30 vs. > 30 days) were evaluated using generalized linear models.

Results: Overall, this study included 16,884,612 hospitalizations with 3,337,266 readmissions among all age groups and 5,977,177 hospitalizations with 1,104,940 readmissions in those aged 18-64 years. Readmission rates decreased in all conditions. In the HRRP announcement period, readmissions declined significantly for those aged 40-64 years for AMI (p < 0.0001) and HF (p = 0.003). Readmissions decreased significantly in the post-HRRP period for those aged 40-64 years at a slower rate for AMI (p = 0.003) and HF (p = 0.05). Readmission rates among younger patients (18-64 years) varied within all four targeted conditions in HRRP announcement and post-HRRP periods. Adjusted models showed a significantly higher readmission cost in those readmitted within 30 days among younger and older populations for AMI (p < 0.0001), HF (p < 0.0001), pneumonia (p < 0.0001), and AECOPD (p < 0.0001).

Conclusion: Readmissions for targeted conditions decreased in the U.S. during the enactment of the HRRP policy and younger age groups (< 65 years) not targeted by the policy saw a mixed effect. Healthcare expenditures in younger and older populations were significantly higher for early readmissions with all targeted conditions. Further research is necessary evaluating total healthcare utilization including emergency department visits, observation units, and hospital readmissions in order to better understand the extent of the HRRP on U.S. healthcare.

Citing Articles

Readmissions and Mortality After "Before Medically Advised" Hospital Discharges Among Medicare Beneficiaries with Opioid Use Disorder.

Benheim T, Kimmel S, George M, Dow P J Gen Intern Med. 2025; .

PMID: 39875771 DOI: 10.1007/s11606-025-09358-0.


Elevating care: assessing the impact of telemonitoring on diabetes management at a cutting-edge quaternary hospital.

Rozzino T, Cardim T, Laselva C, Pires C, Mendonca C, Nascimento M Einstein (Sao Paulo). 2024; 22:eAO0748.

PMID: 39504089 PMC: 11634334. DOI: 10.31744/einstein_journal/2024AO0748.


Rationale and design of healthy at home for COPD: an integrated remote patient monitoring and virtual pulmonary rehabilitation pilot study.

OConnor L, Behar S, Tarrant S, Stamegna P, Pretz C, Wang B Pilot Feasibility Stud. 2024; 10(1):131.

PMID: 39468649 PMC: 11520050. DOI: 10.1186/s40814-024-01560-x.


Patient and social factors related to nebulizer use in COPD patients at the transition of care: a qualitative study.

Foster A, Stoll J, Daly C, Clark C, Sethi S, Jacobs D BMC Pulm Med. 2023; 23(1):358.

PMID: 37740178 PMC: 10517547. DOI: 10.1186/s12890-023-02651-w.


Clinical and economic effectiveness of a pharmacy and primary care collaborative transition of care program.

Jacobs D, Slazak E, Daly C, Clark C, Will S, Meaney D J Am Pharm Assoc (2003). 2023; 63(6):1722-1730.e3.

PMID: 37611896 PMC: 10900124. DOI: 10.1016/j.japh.2023.08.014.


References
1.
Aboumatar H, Naqibuddin M, Chung S, Chaudhry H, Kim S, Saunders J . Effect of a Hospital-Initiated Program Combining Transitional Care and Long-term Self-management Support on Outcomes of Patients Hospitalized With Chronic Obstructive Pulmonary Disease: A Randomized Clinical Trial. JAMA. 2019; 322(14):1371-1380. PMC: 6784754. DOI: 10.1001/jama.2019.11982. View

2.
Jiang X, Xiao H, Segal R, Mobley W, Park H . Trends in Readmission Rates, Hospital Charges, and Mortality for Patients With Chronic Obstructive Pulmonary Disease (COPD) in Florida From 2009 to 2014. Clin Ther. 2018; 40(4):613-626.e1. DOI: 10.1016/j.clinthera.2018.03.006. View

3.
Ranasinghe I, Wang Y, Dharmarajan K, Hsieh A, Bernheim S, Krumholz H . Readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia among young and middle-aged adults: a retrospective observational cohort study. PLoS Med. 2014; 11(9):e1001737. PMC: 4181962. DOI: 10.1371/journal.pmed.1001737. View

4.
Demiralp B, He F, Koenig L . Further Evidence on the System-Wide Effects of the Hospital Readmissions Reduction Program. Health Serv Res. 2017; 53(3):1478-1497. PMC: 5980263. DOI: 10.1111/1475-6773.12701. View

5.
Ibrahim A, Dimick J, Sinha S, Hollingsworth J, Nuliyalu U, Ryan A . Association of Coded Severity With Readmission Reduction After the Hospital Readmissions Reduction Program. JAMA Intern Med. 2017; 178(2):290-292. PMC: 5838609. DOI: 10.1001/jamainternmed.2017.6148. View